[{"orgOrder":0,"company":"Amring Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Amring Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Amring Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amring Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amring Pharma","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Amring Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amring Pharma \/ Amring Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Amring Pharma \/ Amring Pharma"},{"orgOrder":0,"company":"Amring Pharma","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Amring Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amring Pharma \/ Amring Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Amring Pharma \/ Amring Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Amring Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : Preservative-free Timolol Maleate Ophthalmic Solution, USP is supplied in single-dose vials, as a sterile, isotonic, buffered, aqueous solution of timolol maleate and is indicated for treatment of elevated intraocular pressure in patients with ocular hyp...

                          Product Name : Timolol Maleate-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 23, 2022

                          Lead Product(s) : Timolol Maleate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : Under the agreement, Amring granted to Pierre Fabre an exclusive license to exploit and commercialize LYSTEDA (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HM...

                          Product Name : Lysteda

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 29, 2021

                          Lead Product(s) : Tranexamic Acid

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Recipient : Pierre Fabre

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Process Development
                          Not Confirmed
                          Process Development
                          Not Confirmed

                          Details : Acquisition of the global rights to LYSTEDA® (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB), will further strengthen Amring's position in the marketplace...

                          Product Name : Lysteda

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 12, 2020

                          Lead Product(s) : Tranexamic Acid

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Recipient : Ferring Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank